摘要
目的:探讨新型冠状病毒肺炎(COVID-19)患者抗病毒药使用情况,为临床COVID-19患者合理使用抗病毒药提供参考。方法:采用回顾性研究方法,分析2020年2月4日至2020年3月16日黑龙江省传染病防治院(以下简称"我院")治愈出院的51例COVID-19患者的基本信息和抗病毒药使用情况。结果:51例COVID-19患者中,男性患者27例(占52.94%),女性患者24例(占47.06%),男女比例相近;年龄为2~81岁,各年龄段均有发病,以中老年居多;平均住院时间(20.76±7.46)d;严重急性呼吸综合征冠状病毒2型(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)核酸检测转阴时间为5~35 d,平均(18.00±7.07)d;51例患者全部使用了抗病毒药,其中,使用阿比多尔的有49例,使用洛匹那韦/利托那韦的有37例,使用α干扰素的有50例,使用利巴韦林注射液的有11例,使用磷酸奥司他韦胶囊的有2例,使用硫酸羟氯喹的有17例;用药方案主要为阿比多尔、洛匹那韦/利托那韦和α干扰素3种抗病毒药联合应用,极少数患者联合应用4种抗病毒药。结论:我院COVID-19患者抗病毒药的使用基本合理,诊疗方案个体化,但也存在个别患者联合应用3种以上抗病毒药的情况,其安全性和合理性应引起关注。
OBJECTIVE:To probe into the application of antiviral drugs in patients with COVID-19,so as to provide references for the rational application of antiviral drugs in COVID-19 patients.METHODS:Retrospective research was adopted to analyze the basic information and application of antiviral drugs of 51 patients with COVID-19 discharged from the Infectious Disease Hospital of Heilongjiang Province(hereinafter referred to as"our hospital")from Feb.4 th,2020 to Mar.16 th,2020.RESULTS:Among the 51 patients with COVID-19,27 cases were male(52.94%),24 cases were female(47.06%),with similar percentages;aged from 2-81 years old,disease occurred in all age groups,mostly were middle-age and elderly people;with the average length of stay was(20.76±7.46)days;the time of testing negative conversion of nucleic acid of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)was 5-35 days,with an average of(18.00±7.07)days;all the 51 patients had been treated with antiviral drugs,of which 49 cases were given arbidol,37 cases were given lopinavir/ritonavir,50 cases were given interferon-α,11 cases were given ribavirin injection,2 cases was given Oseltamivir phosphate capsule,17 cases were given hydroxychloroquine sulfate;the therapeutic regimen was mainly three-drug combination of arbidol,lopinavir/ritonavir and interferon-α,very few patients was given four-drug combination.CONCLUSIONS:The application of antiviral drugs is basically rational in patients with COVID-19 in our hospital,with individualized diagnosis and treatment scheme,while there are also cases applied more than three-drug combination in individual patients,which needs more attention on its safety and rationality.
作者
孙维佳
徐博学
刘玉琴
SUN Weijia;XU Boxue;LIU Yuqin(Dept.of Pharmacy,Infectious Disease Hospital of Heilongjiang Province,Heilongjiang Harbin 150500,China;Dept.of Internal Medicine-Tuberculosis,Infectious Disease Hospital of Heilongjiang Province,Heilongjiang Harbin 150500,China)
出处
《中国医院用药评价与分析》
2021年第3期362-365,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
作者简介
孙维佳,主任药师。研究方向:医院药学。E-mail:fyj595@163.com;通信作者:刘玉琴,主任医师。研究方向:传染病(结核病)诊疗与管理。E-mail:liuyuqin_ssy@163.com。
